MedTech Dive May 2, 2024
PathAI is selling its diagnostics assets, including a Tennessee laboratory, but will continue to support its biopharmaceutical customers.
Dive Brief:
- Quest Diagnostics said Wednesday it will buy PathAI’s diagnostic laboratory as part of a deal designed to “dramatically ramp” its capabilities in artificial intelligence and digital pathology.
- The lab in Memphis, Tennessee, will become Quest’s AI and digital R&D and solutions center and support the company’s specialty pathology businesses. PathAI is retaining its biopharma lab.
- Quest also secured a license to use PathAI’s digital pathology image management system and to be a preferred provider for the company’s biopharma clinical laboratory services. Neither party disclosed the terms of the deal.
Dive Insight:
PathAI has built a pathology...
Today's Sponsors
Today's Sponsor